GlassScriptPhysician profile
Samuel N Rubenstein
NPI 1548904162
$1,846.47
in general payments reported to CMS, 2019-2025
15 companies · $561 in 2025
The $561 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $266 · 2024: $1,019 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.48 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $411.55 | 2024-2025 | Zoryve |
| Incyte Corporation | $300.77 | 2024-2025 | Opzelura |
| Genzyme Corporation | $224.52 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $213.10 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $158.80 | 2023 | Twyneo, Oracea, Aklief |
| Krystal Biotech INC | $100.69 | 2024 | Vyjuvek |
| Lilly USA, LLC | $96.22 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $94.99 | 2025 | Tremfya |
| Ucb, INC. | $65.04 | 2024-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $55.02 | 2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $30.52 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.33 | 2024 | Spevigo |
| Organogenesis INC. | $24.80 | 2024 | |
| Biofrontera INC. | $21.92 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Helsinn Therapeutics (U.S.), INC. | $21.20 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.